Join
Live feed
·
PRReleasevia Quantisnow
Altimmune Inc. logo

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

ByQuantisnow·Wall Street's wire, on your screen.
ALT· Altimmune Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALT (Altimmune Inc.) and more on Quantisnow.